Asset Details
Do you wish to reserve the book?
Sterol biosynthesis, brain development, and disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sterol biosynthesis, brain development, and disease
Do you wish to request the book?
Sterol biosynthesis, brain development, and disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sterol biosynthesis, brain development, and disease
2026
Overview
Cholesterol biosynthesis is indispensable for CNS development and function. The developing brain relies almost entirely on intrinsic sterol synthesis to support membrane biogenesis, axonal outgrowth, synaptogenesis, and myelination. Pathogenic variants in sterol biosynthetic enzymes, including DHCR7 and DHCR24, result in complex neurodevelopmental disorders such as Smith-Lemli-Opitz syndrome and desmosterolosis. In addition to cholesterol-lowering drugs (statins), some other pharmacological agents such as antipsychotics, antidepressants, and beta blockers can also inhibit cholesterol biosynthesis due to off-target effects. This inhibition produces dual pathophysiological effects: cholesterol depletion and accumulation of its precursor, 7-dehydrocholesterol, an exceptionally oxidizable molecule that spontaneously generates toxic oxysterols. Given the intense demand for cholesterol synthesis in the developing brain, prenatal exposure to sterol biosynthesis–inhibiting medications may have far-reaching effects. In this Review, we describe convergent biochemical, genetic, and epidemiologic data that implicate developmental sterol dysregulation as a modifiable risk factor for neurodevelopmental pathology and underscore the urgent need for routine sterol pathway safety assessment in drug development and prenatal pharmacotherapy.
Publisher
American Society for Clinical Investigation
Subject
/ Animals
/ Brain - growth & development
/ Female
/ Humans
/ Lipid Metabolism, Inborn Errors - genetics
/ Lipid Metabolism, Inborn Errors - metabolism
/ Lipid Metabolism, Inborn Errors - pathology
/ Nerve Tissue Proteins - genetics
/ Nerve Tissue Proteins - metabolism
/ Neurodevelopmental Disorders - genetics
/ Neurodevelopmental Disorders - metabolism
/ Neurodevelopmental Disorders - pathology
/ Oxidoreductases Acting on CH-CH Group Donors - genetics
/ Oxidoreductases Acting on CH-CH Group Donors - metabolism
/ Review
/ Smith-Lemli-Opitz Syndrome - genetics
/ Smith-Lemli-Opitz Syndrome - metabolism
